[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

This Hot Weight-Loss Drug Stock May Have a Surprise Challenger

The global weight-loss drug market has quickly become one of the hottest battlegrounds in healthcare. The explosive popularity of obesity drugs like Wegovy, Ozempic, and Zepbound has created one of the fastest-growing pharmaceutical markets in the world, dominated by giants like Novo Nordisk (NVO) and Eli Lilly (LLY). But now one smaller biotech company — Viking Therapeutics (VKTX) — is drawing attention as a possible surprise challenger, thanks to promising clinical data for its obesity drug candidate VK2735 and plans for potential commercialization.

Let’s find out whether Viking stands a chance in this heated market. 

Fundamentals

See More
  • Market Capitalization, $K 210,212,192
  • Shares Outstanding, K 4,465,000
  • Annual Sales, $ 46,792 M
  • Annual Income, $ 15,509 M
  • EBIT $ 23,190 M
  • EBITDA $ 26,518 M
  • 60-Month Beta 0.77
  • Price/Sales 4.48
  • Price/Cash Flow 10.03
  • Price/Book 6.60

Options Overview Details

View History
  • Implied Volatility 38.62% (-0.59%)
  • Historical Volatility 32.90%
  • IV Percentile 9%
  • IV Rank 10.93%
  • IV High 64.20% on 10/09/25
  • IV Low 35.49% on 12/31/25
  • Expected Move (DTE 7) 1.74 (3.80%)
  • Put/Call Vol Ratio 0.27
  • Today's Volume 47,175
  • Volume Avg (30-Day) 84,411
  • Put/Call OI Ratio 0.69
  • Today's Open Interest 1,531,138
  • Open Int (30-Day) 1,502,556
  • Expected Range 44.06 to 47.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.83
  • Number of Estimates 5
  • High Estimate $0.87
  • Low Estimate $0.78
  • Prior Year $0.97
  • Growth Rate Est. (year over year) -14.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.02 +20.46%
on 04/23/26
47.79 -4.16%
on 05/11/26
+6.48 (+16.48%)
since 04/14/26
3-Month
35.12 +30.41%
on 03/30/26
49.85 -8.12%
on 02/17/26
-3.77 (-7.61%)
since 02/13/26
52-Week
35.12 +30.41%
on 03/30/26
81.44 -43.76%
on 06/13/25
-18.61 (-28.89%)
since 05/14/25

Most Recent Stories

More News
This Hot Weight-Loss Drug Stock May Have a Surprise Challenger

The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player closely.

VKTX : 31.71 (+0.03%)
NVO : 45.80 (-2.72%)
LLY : 1,006.70 (-0.89%)
Hims & Hers Bets Big on GLP-1 Drugs, But Investors Want Profits Now

Hims & Hers delivered a sharp earnings miss as GLP-1 and international expansion costs surged. Investors now face a classic tradeoff between near-term margins and long-term growth.

HIMS : 24.24 (+0.41%)
NVO : 45.80 (-2.72%)
Novo Nordisk A/S Q1 Earnings Call Highlights

Novo Nordisk A/S (NYSE:NVO) said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy pill in the U.S., continued expansion of its obesity franchise and a series of pipeline...

NVO : 45.80 (-2.72%)
Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?

Hims & Hers Health posted a Q1 FY2026 double miss, with an EPS loss of $0.40 and revenue of $608.1 million, sending shares down more than 12% after hours.

HIMS : 24.24 (+0.41%)
NVO : 45.80 (-2.72%)
Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates

EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:PFE),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END

BPC.CN : 0.4850 (+2.11%)
PNGAF : 0.3584 (+6.41%)
NVO : 45.80 (-2.72%)
HIMS : 24.24 (+0.41%)
LLY : 1,006.70 (-0.89%)
PFE : 25.75 (-0.81%)
Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary -- Investor interest in the next-generation wellness market is picking up fast as peptide-based health and performance...

BPC.CN : 0.4850 (+2.11%)
PNGAF : 0.3584 (+6.41%)
NVO : 45.80 (-2.72%)
HIMS : 24.24 (+0.41%)
LLY : 1,006.70 (-0.89%)
PFE : 25.75 (-0.81%)
Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus

As Hims & Hers pivots to branded GLP-1s via a Novo Nordisk deal, all eyes are on the company’s May 11 earnings as investors look for sustained subscriber growth.

HIMS : 24.24 (+0.41%)
NVO : 45.80 (-2.72%)
What the FDA's Latest Proposal Means for Lilly, Novo, and Hims

The FDA's latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would also garner indirect benefits.

NVO : 45.80 (-2.72%)
LLY : 1,006.70 (-0.89%)
Biotech’s Next Wave May Already be in Motion

DENVER, May 07, 2026 (GLOBE NEWSWIRE) -- ( www.247marketnews.com and NeOnc Technology) - The biotech and pharma sector is entering one of its most pivotal periods in years, where insider conviction,...

NTHI : 5.46 (+0.74%)
NVO : 45.80 (-2.72%)
LLY : 1,006.70 (-0.89%)
REGN : 712.87 (-0.97%)
Novo Nordisk Reports Earnings While Trading Like the Obesity Boom Already Ended

Barchart Research What to Expect from NVO Earnings NVO Generated May 5, 2026 Current Price $44.87 EPS Estimate $$0.87 Consensus Rating Hold Average Move 4.47% Novo Nordisk Reports Earnings While Trading...

NVO : 45.80 (-2.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 47.88
2nd Resistance Point 47.36
1st Resistance Point 46.58
Last Price 45.80
1st Support Level 45.28
2nd Support Level 44.76
3rd Support Level 43.98

See More

52-Week High 81.44
Fibonacci 61.8% 63.75
Fibonacci 50% 58.28
Fibonacci 38.2% 52.81
Last Price 45.80
52-Week Low 35.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.